Amgen Chief Executive Officer Robert Bradway is excited about 2022. During his presentation at the J.P. Morgan Healthcare Conference, Bradway said things are lining up for long-term growth for the California-based company.
Shares of GlaxoSmithKline climbed in trading on rumors that the consumer health business it intends to spin off into a separate company next year is attracting interest from venture capitalists.
One month after GlaxoSmithKline outlined plans for the company’s future following a planned split between its pharmaceuticals and consumer health businesses, GSK posted second-quarter 2021 sales of £8.1 billion ($11.2 billion).
A day after activist investor Elliott Management called on GlaxoSmithKline to sack Chief Executive Officer Emma Walmsley and line up new leadership for the pharma company when it splits into two entities, GSK’s board of directors soundly rejected the demand.
Activist investor Elliott Management continues to push for a change in leadership at GlaxoSmithKline ahead of the planned 2022 split of the company.